Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Harvard Business School
Merck
McKesson
Boehringer Ingelheim

Last Updated: October 14, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for DDP-225

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug DDP-225: Patents, clinical trial progress, indications

DDP-225 is an investigational drug.

There have been 29 clinical trials for DDP-225. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.

The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Peking University, and First Affiliated Hospital of Guangxi Medical University.

There are twelve US patents protecting this investigational drug and one hundred and forty-one international patents.

Recent Clinical Trials for DDP-225
TitleSponsorPhase
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).Henan Cancer HospitalPhase 2
GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPCGuiyang Medical UniversityPhase 3

See all DDP-225 clinical trials

Clinical Trial Summary for DDP-225

Top disease conditions for DDP-225
Top clinical trial sponsors for DDP-225

See all DDP-225 clinical trials

US Patents for DDP-225

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
DDP-225   See Pricing Use of 4-(2-Flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidin- e for treating of urinary incontinence Arachnova Therapeutics Ltd. (Jersey, GB)   See Pricing
DDP-225   See Pricing 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder Dynogen Pharmaceuticals, Inc. (Waltham, MA)   See Pricing
DDP-225   See Pricing Substituted phenoxy thiazolidinediones as estrogen related receptor-.alpha. modulators Janssen Pharmaceutica, NV (Beerse, BE)   See Pricing
DDP-225   See Pricing Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-.alpha. modulators Janssen Pharmaceutica N.V. (Beerse, BE)   See Pricing
DDP-225   See Pricing Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators Janssen Pharmaceutica NV (Beerse, BE)   See Pricing
DDP-225   See Pricing Substituted phenoxy thiazolidinediones as estrogen related receptor-a modulators Janssen Pharmaceutica, NV (Beerse, BE)   See Pricing
DDP-225   See Pricing Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators Janssen Pharmaceutica NV (Beerse, BE)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for DDP-225

Drugname Country Document Number Estimated Expiration Related US Patent
DDP-225 Austria 397448 2022-01-31   See Pricing
DDP-225 Australia 2003205836 2022-01-31   See Pricing
DDP-225 Brazil 0307369 2022-01-31   See Pricing
DDP-225 Canada 2474851 2022-01-31   See Pricing
DDP-225 China 1279915 2022-01-31   See Pricing
DDP-225 China 1625402 2022-01-31   See Pricing
DDP-225 Germany 60321445 2022-01-31   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKesson
McKinsey
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.